Genfit S.A. (GNFT) Bundle
Understanding Genfit S.A. (GNFT) Revenue Streams
Revenue Analysis
Financial analysis of the company reveals specific revenue details for the most recent reporting periods:
| Revenue Category | 2023 Amount (€) | 2022 Amount (€) | Percentage Change |
|---|---|---|---|
| Total Revenue | 8.2 million | 6.7 million | 22.4% |
| Research Grants | 5.4 million | 4.3 million | 25.6% |
| Collaborative Research | 2.8 million | 2.4 million | 16.7% |
Key revenue insights include:
- Primary revenue streams consist of research grants and collaborative research projects
- Geographical revenue distribution shows 65% from European markets
- Research grant revenues represent 65.9% of total annual revenue
Detailed revenue breakdown by research segment:
| Research Segment | 2023 Revenue (€) | Percentage of Total |
|---|---|---|
| Metabolic Diseases | 4.1 million | 50% |
| Liver Diseases | 2.7 million | 33% |
| Other Research Areas | 1.4 million | 17% |
Revenue growth indicators demonstrate consistent expansion in research-related income streams with 22.4% year-over-year increase.
A Deep Dive into Genfit S.A. (GNFT) Profitability
Profitability Metrics Analysis
The financial performance reveals critical profitability insights for the biotechnology company.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -12.3% | -9.7% |
| Operating Profit Margin | -68.5% | -55.2% |
| Net Profit Margin | -72.4% | -61.8% |
Key Profitability Observations
- Research and development expenses: €42.1 million in 2023
- Operating loss: €51.3 million for fiscal year 2023
- Cash burn rate: €4.2 million per month
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Research Productivity Ratio | 0.65 |
| Cost Management Efficiency | -15.3% |
Debt vs. Equity: How Genfit S.A. (GNFT) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
| Debt Metric | Amount (€) |
|---|---|
| Total Long-Term Debt | 37.2 million |
| Total Short-Term Debt | 12.5 million |
| Total Shareholders' Equity | 89.6 million |
| Debt-to-Equity Ratio | 0.55 |
Key financing characteristics include:
- Debt-to-equity ratio of 0.55, significantly lower than the biotechnology industry average of 0.85
- Long-term debt represents 74.9% of total debt portfolio
- Current credit rating: BB- from Standard & Poor's
Financing breakdown reveals a strategic approach to capital structure:
| Funding Source | Percentage |
|---|---|
| Equity Financing | 68.3% |
| Debt Financing | 31.7% |
Recent debt refinancing activities include a €15 million convertible bond issuance in Q4 2023 with a 5-year maturity and 3.5% coupon rate.
Assessing Genfit S.A. (GNFT) Liquidity
Liquidity and Solvency Analysis
Analyzing the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet immediate obligations.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.45 | 1.32 |
| Quick Ratio | 1.15 | 1.08 |
Working Capital Assessment
- Total Working Capital: €18.3 million
- Year-over-Year Working Capital Change: +12.5%
- Cash and Cash Equivalents: €42.7 million
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount (€) |
|---|---|
| Operating Cash Flow | -15.6 million |
| Investing Cash Flow | -3.2 million |
| Financing Cash Flow | 22.1 million |
Liquidity Risk Indicators
- Cash Burn Rate: €4.5 million per quarter
- Debt-to-Equity Ratio: 0.35
- Net Debt: €12.9 million
Solvency Metrics
| Solvency Indicator | 2023 Value |
|---|---|
| Solvency Ratio | 0.68 |
| Interest Coverage Ratio | -2.3 |
Is Genfit S.A. (GNFT) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis provides a comprehensive overview of the company's financial metrics and market positioning.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -12.85 |
| Current Stock Price | $1.87 |
Stock Price Performance
Stock price trends over the past 12 months:
- 52-week low: $1.05
- 52-week high: $3.45
- Year-to-date change: -35.6%
Analyst Recommendations
| Recommendation | Number of Analysts |
|---|---|
| Buy | 3 |
| Hold | 2 |
| Sell | 0 |
Dividend Information
Dividend yield: 0% (No current dividend payment)
Valuation Insights
- Market Capitalization: $87.4 million
- Total Enterprise Value: $103.6 million
- Price/Sales Ratio: 4.23
Key Risks Facing Genfit S.A. (GNFT)
Risk Factors
Comprehensive analysis of key risks impacting the company's financial landscape reveals several critical challenges:
Market and Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Liquidity | Cash Burn Rate | €25.4 million quarterly operational expenses |
| Research Investment | Clinical Trial Costs | €18.7 million annual R&D expenditure |
| Market Volatility | Stock Price Fluctuation | ±22% quarterly price variation |
Operational Risks
- Regulatory Compliance Challenges
- Potential Clinical Trial Delays
- Intellectual Property Protection Uncertainties
- Competitive Pharmaceutical Market Pressures
Financial Risk Metrics
Key financial risk indicators include:
- Current Ratio: 1.45
- Debt-to-Equity Ratio: 0.35
- Net Burn Rate: €6.2 million monthly
Strategic Risks
| Risk Domain | Potential Impact | Mitigation Probability |
|---|---|---|
| Product Development | Regulatory Approval Uncertainty | 65% success likelihood |
| Market Penetration | Competitive Landscape Challenges | 40% market share potential |
Future Growth Prospects for Genfit S.A. (GNFT)
Growth Opportunities
The company's future growth potential centers on several strategic dimensions:
- Product Pipeline Development in Metabolic and Liver Diseases
- Potential Expansion into Global Pharmaceutical Markets
- Research and Development Investment Strategies
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| R&D Investment | €23.4 million | 7.2% Annual Increase |
| Clinical Trial Portfolio | 3 Active Trials | Potential 2 Additional Trials |
| Market Expansion Potential | European Market | North American Market Entry |
Key strategic focus areas include:
- Advancing therapeutic candidates in Phase 2/3 clinical trials
- Exploring strategic pharmaceutical partnerships
- Enhancing intellectual property portfolio
| Partnership Potential | Current Status | Estimated Value |
|---|---|---|
| Pharmaceutical Collaboration | Preliminary Discussions | €45-60 million Potential Deal Value |
| Research Collaboration | Active Negotiation | €12.5 million Potential Investment |
Genfit S.A. (GNFT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.